QUICK SEARCH:   [advanced] Author: Keyword(s):
Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents

This Article Figures Only Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jin, S. Articles by Levine, A. J. Search for Related Content PubMed PubMed Citation Articles by Jin, S. Articles by Levine, A. J. Social Bookmarking                         What's this?

The p53 functional circuit

The Rockefeller University, 1230 York Avenue, New York, NY 10021, USA

*Author for correspondence (e-mail: alevine{at}mail.rockefeller.edu)

The p53 gene is a tumor suppressor gene that plays a critical role in safeguarding the integrity of the genome. p53 is mutated or part of its regulatory circuit is functionally inactivated in almost all cancers, which highlights its importance in preventing tumorigenesis. The p53 protein is a sequence-specific DNA-binding transcription factor that is kept at a low level in cells under normal circumstances. Various stress signals, such as DNA damage, can stabilize and activate p53. Upon activation, p53 binds to the enhancer/promoter elements of downstream target genes and regulates their transcription, through which it initiates cellular programs that account for most of its tumor-suppressor functions.

The functional signal transduction circuit of p53 consists of the upstream mediators (which sense and relay stress signals to p53), the core regulation components (which form the core circuitry maintaining and regulating p53 levels) and the downstream effectors (which initiate cellular response programs).

The core regulatory circuitry consists of p53, Mdm2, p14^ARF (p19^Arf in the mouse) and E2F-1. These are organized into two interactive feedback loops. p53 and Mdm2 form one feedback loop, in which p53 positively regulates Mdm2 by activating Mdm2 transcription, and Mdm2 negatively regulates p53 by promoting p53 ubiquitination and degradation. E2F-1 and p14^ARF form a similar feedback loop, in which E2F-1 activates ARF transcription, and p14^ARF facilitates proteolytic degradation of E2F-1. These two feedback loops are connected in two ways. First, p14^ARF interacts with Mdm2, inhibiting Mdm2-mediated p53 ubiquitination and degradation, thereby stabilizing p53. Second, p53 represses transcription of the ARF gene. This complex circuit is essential for maintaining and regulating p53 intracellular levels and activities. Some aspects of this circuit are defective in all cancers. Missense mutations of p53, amplification of MDM2, silencing or deletion of ARF and/or the loss of E2F-1 regulation through RB mutation are the most common mechanisms by which tumor cells alter the circuitry.

Cellular stresses signal to p53 by perturbing the p53 core regulatory circuitry directly or indirectly. Several stresses activate p53, including DNA damage, oncogene activation, hypoxia, cellular ribonucleotide depletion, mitotic spindle damage and nitric oxide (NO) production. DNA damage activates p53 through p53 upstream mediators, which include protein kinases, transcriptional coactivator complexes with histone (protein) acetyltransferase activity, transcriptional co-repressor complexes with histone (protein) deacetylase activity, and other p53 activity modulators, such as Sumo-1 ligases, PML complex, Werner’s Syndrome protein (WRN) and HMG-1 protein. Most of these upstream mediators target p53 for post-translational modification. For example, DNA damage activates the protein kinases ATM, ATR, CHK1 and CHK2, which in turn phosphorylate p53 and/or Mdm2. Phosphorylation of p53 and/or Mdm2 activates p53 through three mechanisms: (1) stabilizing p53 by disrupting p53-Mdm2 interaction; (2) regulating p53 transactivation activity; (3) promoting p53 nuclear localization. Activated p53 recruits transcriptional coactivator or co-repressor complexes to the enhancer/promoter regions of its downstream target genes, facilitating or repressing their transcription, respectively. These transcription cofactor complexes can either acetylate or deacetylate p53 itself, which increases or decreases p53 stability and its DNA-binding affinity, respectively. In addition, another post-translational modification, sumoylation, of p53 appears to modulate p53 levels and activity. In contrast, oncogenes usually regulate p53 by altering transcription and/or activity of the ARF gene. For example, the oncogenes E2F-1, Ras, DMP1 and Myc enhance ARF transcription, whereas Twist, Bmi-1 and TBX2 downregulate it. The mechanisms by which other stresses activate p53 are not fully understood.

Upon activation, p53 in turn activates or represses the transcription of its downstream effector genes, through which it may trigger several cellular programs, including cell cycle arrest, apoptosis, inhibition of angiogenesis/metastasis, and DNA repair. p53 may induce G1-S arrest by activating p21, a CDK2 inhibitor, or it may trigger G2-M arrest by inducing 14-3-3, GADD45, Reprimo and b99, which leads to CDC2 inhibition. p53 induces apoptosis by activating many pro-apoptosis genes, which ultimately activate Apaf-1 and caspase 9 through several pathways. p53 can activate anti-angiogenesis genes such as TSP1, BAI-1, MASPIN, GD-AiF and anti-metastasis genes such as KAI. p53 can also activate genes involved in DNA repair, including p48 in the nucleotide excision repair (NER) pathway and non-S-phase ribonucleotide reductase (R2). Finally, p53 can activate or repress genes that have undefined functions. Among these are those that encode cyclin G, EF-I, Wip1 and Map4. Different types of cellular stress in cells of different tissue types appear to regulate different transcriptional programs by activating a subset of these genes and their products.

View larger version (59K): [in this window] [in a new window]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				W. Fu, Q. Ma, L. Chen, P. Li, M. Zhang, S. Ramamoorthy, Z. Nawaz, T. Shimojima, H. Wang, Y. Yang, et al. MDM2 Acts Downstream of p53 as an E3 Ligase to Promote FOXO Ubiquitination and Degradation J. Biol. Chem., May 22, 2009; 284(21): 13987 - 14000. [Abstract] [Full Text] [PDF]

				J. N. Bartholomew, D. Volonte, and F. Galbiati Caveolin-1 Regulates the Antagonistic Pleiotropic Properties of Cellular Senescence through a Novel Mdm2/p53-Mediated Pathway Cancer Res., April 1, 2009; 69(7): 2878 - 2886. [Abstract] [Full Text] [PDF]

				R. Rani, J. Li, and Q. Pang Differential p53 Engagement in Response to Oxidative and Oncogenic Stresses in Fanconi Anemia Mice Cancer Res., December 1, 2008; 68(23): 9693 - 9702. [Abstract] [Full Text] [PDF]

				C. Chu and A. J. Shatkin Apoptosis and Autophagy Induction in Mammalian Cells by Small Interfering RNA Knockdown of mRNA Capping Enzymes Mol. Cell. Biol., October 1, 2008; 28(19): 5829 - 5836. [Abstract] [Full Text] [PDF]

				K. Asomaning, A. E. Reid, W. Zhou, R. S. Heist, R. Zhai, L. Su, E. L. Kwak, L. Blaszkowsky, A. X. Zhu, D. P. Ryan, et al. MDM2 Promoter Polymorphism and Pancreatic Cancer Risk and Prognosis Clin. Cancer Res., June 15, 2008; 14(12): 4010 - 4015. [Abstract] [Full Text] [PDF]

				A. Zaky, C. Busso, T. Izumi, R. Chattopadhyay, A. Bassiouny, S. Mitra, and K. K. Bhakat Regulation of the human AP-endonuclease (APE1/Ref-1) expression by the tumor suppressor p53 in response to DNA damage Nucleic Acids Res., March 1, 2008; 36(5): 1555 - 1566. [Abstract] [Full Text] [PDF]

				Y. Qian, J. Zhang, B. Yan, and X. Chen DEC1, a Basic Helix-Loop-Helix Transcription Factor and a Novel Target Gene of the p53 Family, Mediates p53-dependent Premature Senescence J. Biol. Chem., February 1, 2008; 283(5): 2896 - 2905. [Abstract] [Full Text] [PDF]

				B. Oster, B. Bundgaard, T. R. Hupp, and P. Hollsberg Human herpesvirus 6B induces phosphorylation of p53 in its regulatory domain by a CK2- and p38-independent pathway J. Gen. Virol., January 1, 2008; 89(1): 87 - 96. [Abstract] [Full Text] [PDF]

				G. Deep, N. H. Oberlies, D. J. Kroll, and R. Agarwal Isosilybin B and isosilybin A inhibit growth, induce G1 arrest and cause apoptosis in human prostate cancer LNCaP and 22Rv1 cells Carcinogenesis, July 1, 2007; 28(7): 1533 - 1542. [Abstract] [Full Text] [PDF]

				E. A. O'Brien, V. Barnes, L. Zhao, R. A. McKnight, X. Yu, C. W. Callaway, L. Wang, J. C. Sun, M. J. Dahl, A. Wint, et al. Uteroplacental insufficiency decreases p53 serine-15 phosphorylation in term IUGR rat lungs Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2007; 293(1): R314 - R322. [Abstract] [Full Text] [PDF]

				R. S. Heist, W. Zhou, L. R. Chirieac, T. Cogan-Drew, G. Liu, L. Su, D. Neuberg, T. J. Lynch, J. C. Wain, and D. C. Christiani MDM2 Polymorphism, Survival, and Histology in Early-Stage Non-Small-Cell Lung Cancer J. Clin. Oncol., June 1, 2007; 25(16): 2243 - 2247. [Abstract] [Full Text] [PDF]

				L. A. Fecher, S. D. Cummings, M. J. Keefe, and R. M. Alani Toward a Molecular Classification of Melanoma J. Clin. Oncol., April 20, 2007; 25(12): 1606 - 1620. [Abstract] [Full Text] [PDF]

				W. Hu, Z. Feng, L. Ma, J. Wagner, J. J. Rice, G. Stolovitzky, and A. J. Levine A Single Nucleotide Polymorphism in the MDM2 Gene Disrupts the Oscillation of p53 and MDM2 Levels in Cells Cancer Res., March 15, 2007; 67(6): 2757 - 2765. [Abstract] [Full Text] [PDF]

				G. S. Atwal, G. L. Bond, S. Metsuyanim, M. Papa, E. Friedman, T. Distelman-Menachem, E. Ben Asher, D. Lancet, D. A. Ross, J. Sninsky, et al. Haplotype structure and selection of the MDM2 oncogene in humans PNAS, March 13, 2007; 104(11): 4524 - 4529. [Abstract] [Full Text] [PDF]

				J. Yan, J. Jiang, C. A. Lim, Q. Wu, H.-H. Ng, and K.-C. Chin BLIMP1 regulates cell growth through repression of p53 transcription PNAS, February 6, 2007; 104(6): 1841 - 1846. [Abstract] [Full Text] [PDF]

				N. Ohmiya, A. Taguchi, N. Mabuchi, A. Itoh, Y. Hirooka, Y. Niwa, and H. Goto MDM2 Promoter Polymorphism Is Associated With Both an Increased Susceptibility to Gastric Carcinoma and Poor Prognosis J. Clin. Oncol., September 20, 2006; 24(27): 4434 - 4440. [Abstract] [Full Text] [PDF]

				M. Baserga, M. A. Hale, X. Ke, Z. M. Wang, X. Yu, C. W. Callaway, R. A. McKnight, and R. H. Lane Uteroplacental insufficiency increases p53 phosphorylation without triggering the p53-MDM2 functional circuit response in the IUGR rat kidney Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2006; 291(2): R412 - R418. [Abstract] [Full Text] [PDF]

				B. F. Taylor, S. C. McNeely, H. L. Miller, G. M. Lehmann, M. J. McCabe Jr., and J. C. States p53 Suppression of Arsenite-Induced Mitotic Catastrophe Is Mediated by p21CIP1/WAF1 J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 142 - 151. [Abstract] [Full Text] [PDF]

				X. Yu, S. L. Harris, and A. J. Levine The Regulation of Exosome Secretion: a Novel Function of the p53 Protein. Cancer Res., May 1, 2006; 66(9): 4795 - 4801. [Abstract] [Full Text] [PDF]

				H. Arakawa, F. Wu, M. Costa, W. Rom, and M.-s. Tang Sequence specificity of Cr(III)-DNA adduct formation in the p53 gene: NGG sequences are preferential adduct-forming sites Carcinogenesis, March 1, 2006; 27(3): 639 - 645. [Abstract] [Full Text] [PDF]

				G. Liu and X. Chen DNA Polymerase {eta}, the Product of the Xeroderma Pigmentosum Variant Gene and a Target of p53, Modulates the DNA Damage Checkpoint and p53 Activation Mol. Cell. Biol., February 15, 2006; 26(4): 1398 - 1413. [Abstract] [Full Text] [PDF]

				A. J. Levine, Z. Feng, T. W. Mak, H. You, and S. Jin Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways Genes & Dev., February 1, 2006; 20(3): 267 - 275. [Abstract] [Full Text] [PDF]

				L. Ma, J. Wagner, J. J. Rice, W. Hu, A. J. Levine, and G. A. Stolovitzky A plausible model for the digital response of p53 to DNA damage PNAS, October 4, 2005; 102(40): 14266 - 14271. [Abstract] [Full Text] [PDF]

				G. L. Bond, W. Hu, and A. Levine A Single Nucleotide Polymorphism in the MDM2 Gene: From a Molecular and Cellular Explanation to Clinical Effect Cancer Res., July 1, 2005; 65(13): 5481 - 5484. [Abstract] [Full Text] [PDF]

				Z. Feng, H. Zhang, A. J. Levine, and S. Jin The coordinate regulation of the p53 and mTOR pathways in cells PNAS, June 7, 2005; 102(23): 8204 - 8209. [Abstract] [Full Text] [PDF]

				A. A. Gridasova and R. W. Henry The p53 Tumor Suppressor Protein Represses Human snRNA Gene Transcription by RNA Polymerases II and III Independently of Sequence-Specific DNA Binding Mol. Cell. Biol., April 15, 2005; 25(8): 3247 - 3260. [Abstract] [Full Text] [PDF]

				X. Ke, R. A. McKnight, Z.-m. Wang, X. Yu, L. Wang, C. W. Callaway, K. H. Albertine, and R. H. Lane Nonresponsiveness of cerebral p53-MDM2 functional circuit in newborn rat pups rendered IUGR via uteroplacental insufficiency Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2005; 288(4): R1038 - R1045. [Abstract] [Full Text] [PDF]

				S.L. HARRIS, G. GIL, W. HU, H. ROBINS, E. BOND, K. HIRSHFIELD, Z. FENG, X. YU, A.K. TERESKY, G. BOND, et al. Single-Nucleotide Polymorphisms in the p53 Pathway Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 111 - 119. [Abstract] [PDF]

				P.-K. Lo, S.-Z. Huang, H.-C. Chen, and F.-F. Wang The Prosurvival Activity of p53 Protects Cells from UV-Induced Apoptosis by Inhibiting c-Jun NH2-terminal Kinase Activity and Mitochondrial Death Signaling Cancer Res., December 1, 2004; 64(23): 8736 - 8745. [Abstract] [Full Text] [PDF]

				H. A. Rogoff, M. T. Pickering, F. M. Frame, M. E. Debatis, Y. Sanchez, S. Jones, and T. F. Kowalik Apoptosis Associated with Deregulated E2F Activity Is Dependent on E2F1 and Atm/Nbs1/Chk2 Mol. Cell. Biol., April 1, 2004; 24(7): 2968 - 2977. [Abstract] [Full Text] [PDF]

				S. Haupt, M. Berger, Z. Goldberg, and Y. Haupt Apoptosis - the p53 network J. Cell Sci., October 15, 2003; 116(20): 4077 - 4085. [Abstract] [Full Text] [PDF]

				M. Overholtzer, P. H. Rao, R. Favis, X.-Y. Lu, M. B. Elowitz, F. Barany, M. Ladanyi, R. Gorlick, and A. J. Levine The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability PNAS, September 30, 2003; 100(20): 11547 - 11552. [Abstract] [Full Text] [PDF]

				S. Jin, M. Kalkum, M. Overholtzer, A. Stoffel, B. T. Chait, and A. J. Levine CIAP1 and the serine protease HTRA2 are involved in a novel p53-dependent apoptosis pathway in mammals Genes & Dev., February 1, 2003; 17(3): 359 - 367. [Abstract] [Full Text] [PDF]

				J. Hoh, S. Jin, T. Parrado, J. Edington, A. J. Levine, and J. Ott The p53MH algorithm and its application in detecting p53-responsive genes PNAS, June 25, 2002; 99(13): 8467 - 8472. [Abstract] [Full Text] [PDF]

This Article Figures Only Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jin, S. Articles by Levine, A. J. Search for Related Content PubMed PubMed Citation Articles by Jin, S. Articles by Levine, A. J. Social Bookmarking                         What's this?